Vaxcyte is a clinical-stage vaccine company developing broader-coverage pneumococcal conjugate vaccines. Its approach uses a cell-free protein synthesis platform intended to enable more serotypes than traditional conjugate methods. Lead candidates target prevention of invasive pneumococcal disease in adults and children; commercial revenue is not yet material.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -166.6 | — |
| Q3 2025 | 0 | — | -212.8 | — |
| Q4 2025 | 0 | — | -246.5 | — |
| Q1 2026 | 0 | — | -320.6 | — |
| Q2 2026 | 0 | — | -284.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: UMB Financial Corporation (UMBF), TTM Technologies, Inc. (TTMI), Match Group, Inc. (MTCH), Henry Schein, Inc. (HSIC), Insulet Corporation (PODD), Enlight Renewable Energy Ltd (ENLT)